The Danish firm announced the recall last week, explaining the move followed “two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection (SWFI).”
The GlucaGen HypoKit pen – which has been available in the US since 2005 - is used to deliver a recombinant version of the peptide hormone glucagon. It is used to treat severe hypoglycemia – low blood sugar – in patients with insulin-dependent diabetes.
Novo spokeswoman Mette Kruse Danielsen told us “the root cause was a manufacturing error at the supplier of the glass syringe that is used together with the vial containing freeze dried glucagon.”
Danielsen also confirmed the device was made by a third party, but declined to name the company involved.
She added that: “Novo Nordisk has in cooperation with the supplier instituted corrective actions to avoid re-occurrence."
Note: Our email newsletter strap line incorrectly stated that the recalled product is an "insulin pen."